Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Multicenter Evaluation of Patients with Cutaneous Malignant Melanoma in Turkey: MELAS Study

  • Uysal-Sonmez, Ozlem (Department of Medical Oncology, Sakarya University Education and Research Hospital) ;
  • Tanriverdi, Ozgur (Department of Medical Oncology, Mugla Sitki Kocman University Education and Research Hospital) ;
  • Esbah, Onur (Clinic of Medical Oncology, Dr. Abdurrahman Yurtarslan Oncology Education and Research Hospital) ;
  • Uyeturk, Ummugul (Division of Medical Oncology, Department of Internal Medicine, Abant Izzet Baysal University Faculty of Medicine) ;
  • Helvaci, Kaan (Clinic of Medical Oncology, Dr. Abdurrahman Yurtarslan Oncology Education and Research Hospital) ;
  • Bal, Oznur (Clinic of Medical Oncology, Dr. Abdurrahman Yurtarslan Oncology Education and Research Hospital) ;
  • Yalcintas-Arslan, Ulku (Clinic of Medical Oncology, Dr. Abdurrahman Yurtarslan Oncology Education and Research Hospital) ;
  • Budakoglu, Burcin (Clinic of Medical Oncology, Dr. Abdurrahman Yurtarslan Oncology Education and Research Hospital) ;
  • Oksuzoglu, Berna (Clinic of Medical Oncology, Dr. Abdurrahman Yurtarslan Oncology Education and Research Hospital)
  • Published : 2013.01.31
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Malignant melanoma is a cancer that demonstrates rapid progression and atypical clinically features with a poor prognosis. Aim: This study was performed to determine the clinical characteristics and treatment outcomes of patients with malignant melanoma in Turkey. Methods: The medical records of 98 patients between 2007-2012 at our centers were retrieved from the patient registry. Overall survival (OS) was calculated using the Kaplan-Meier method. Results: In our study, with the median follow-up of all patients with cutaneous MM of 46.3 months, the median OS rate of all cases was 43.6 months and 5-year OS was 48.6%. However, five-year OS rates of patients with localized disease (stage I-II) and node involvement (stage III) were 60.3% and 39.6%, respectively. The median OS of stage IV patients was 8.7 months and 1-year OS rate was 26.2%. We showed that advanced stage, male gender, and advanced age in all patients with MM were significant prognostic factors of OS. Conclusions: Compared with the results of current studies from Western countries, we found similar findings concerning demographical features, histological variables and survival analyses for our patients with cutaneous MM in Turkey.

Keywords

References

  1. Balch CM, Buzaid AC, Soong SJ, et al (2001). Final version of the American joint committee on cancer staging system for cutaneous melanoma. J Clin Oncol, 19, 3635-48.
  2. Barnhill RL, Fine JA, Roush GC, Berwick M (1996). Predicting five-year outcome for patients with cutaneous melanoma in a population-based study. Cancer, 78, 427-32. https://doi.org/10.1002/(SICI)1097-0142(19960801)78:3<427::AID-CNCR8>3.0.CO;2-G
  3. Chao C, Martin RC, Ross MI, et al (2004). Correlation between prognostic factors and increasing age in melanoma. Ann Surg Oncol, 11, 259-64. https://doi.org/10.1245/ASO.2004.04.015
  4. Chi Z, Li S, Sheng X, et al (2011). Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases. BMC Cancer, 11, 85-95. https://doi.org/10.1186/1471-2407-11-85
  5. Gimotty PA, Botbyl J, Soong SH, Guerry D (2005). A population-based validation of the American Joint Committee on Cancer melanoma staging systemç. J Clin Oncol, 23, 8065-75. https://doi.org/10.1200/JCO.2005.02.4976
  6. Hainsworth JD, Infante JR, Spigel DR, et al (2010). Bevacizumab and everolimus in the treatment of patients with metastatic melanoma: a phase 2 trial of the Sarah cannon oncology research consortium. Cancer, 116, 4122-9. https://doi.org/10.1002/cncr.25320
  7. Hauschild A, Agarwala SS, Trefzer U, et al (2009). Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol, 27, 2823-30. https://doi.org/10.1200/JCO.2007.15.7636
  8. Jemal A, Siegel R, Ward E, et al (2009). Cancer statistics, 2009. CA Cancer J Clin, 59, 225-49. https://doi.org/10.3322/caac.20006
  9. Lasithiotakis K, Leiter U, Meier F, et al (2008). Age and gender are significant independent predictors of survival in primary cutaneous melanoma. Cancer, 112, 1795-804. https://doi.org/10.1002/cncr.23359
  10. Lindholm C, Andersson R, Dufmats M, et al (2004). Invasive cutaneous malignant melanoma in Sweden, 1990-1999. A prospective, population-based study of survival and prognostic factors. Cancer, 101, 2067-78. https://doi.org/10.1002/cncr.20602
  11. MacKie RM, Bray C, Vestey J, et al (2007). Melanoma incidence and mortality in Scotland 1979-2003. Br J Cancer, 96, 1772-7. https://doi.org/10.1038/sj.bjc.6603801
  12. Markovic SN, Erickson LA, Rao RD, et al (2007). Malignant melanoma in the 21st century, part 2: staging, prognosis, and treatment. Mayo Clin Proc, 82, 490-513. https://doi.org/10.4065/82.4.490
  13. Mervic L (2012). Prognostic factors in patients with localized primary cutaneous melanoma. Acta Dermatovenerologica, 21, 27-31.
  14. O'Day S, Hodi FS, McDermott DF, et al (2010). A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma. J Clin Oncol, 28, 4. https://doi.org/10.1200/JCO.2009.23.3890
  15. Reed KB, Brewer JD, Lohse CM, et al (2012). Increasing incidence of melanoma among young adults: an epidemiological study in Olmsted County, Minnesota. Mayo Clin Proc, 87, 328-34. https://doi.org/10.1016/j.mayocp.2012.01.010
  16. Spatz A, Cook MG, Elder DE, et al (2003). Interobserver reproducibility of ulceration assessment in primary cutaneous melanomas. Eur J Cancer, 39, 1861-5. https://doi.org/10.1016/S0959-8049(03)00325-3
  17. Tas F, Kurul S, Camlica H, Topuz E (2006). Malignant melanoma in Turkey: a single institution’s experience on 475 cases. Jpn J Clin Oncol, 36, 784-9.
  18. Thompson JF, Soong SJ, Balch CM, et al (2011). Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American joint committee on cancer melanoma staging database. J Clin Oncol, 29, 2199-205. https://doi.org/10.1200/JCO.2010.31.5812
  19. Uehara S, Kamo R, Harada T, Ishii M (2009). Survival analysis of malignant melanoma in Japan-multivariate analysis of prognostic factors. Osaka City Med J, 55, 35-52.
  20. Verma S, Quirt I, McCready D, et al (2006). Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma. Cancer, 106, 1431-42. https://doi.org/10.1002/cncr.21760

Cited by

  1. Assessing a Sun Protection Program Aimed at Greek Elementary School Students for Malign Melanoma Prevention vol.15, pp.12, 2014, https://doi.org/10.7314/APJCP.2014.15.12.5009
  2. A Retrospective Multicenter Evaluation of Cutaneous Melanomas in Turkey vol.15, pp.23, 2015, https://doi.org/10.7314/APJCP.2014.15.23.10451
  3. Tumors Involving Skin, Soft Tissue and Skeletal Muscle: Benign, Primary Malignant or Metastatic? vol.16, pp.15, 2015, https://doi.org/10.7314/APJCP.2015.16.15.6681
  4. The role of BRAF mutation in patients with high-risk malignant melanoma treated with high-dose adjuvant interferon therapy vol.32, pp.1, 2015, https://doi.org/10.1007/s12032-014-0440-7
  5. An update on cutaneous melanoma in Turkey: evaluation of 19-year data in a single tertiary centre and review of the literature vol.31, pp.2, 2017, https://doi.org/10.1111/jdv.13866